Ischemic Stroke
Conditions
Keywords
ischemic, stroke, vitamin B2
Brief summary
Administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemic stroke to know if it causes a reduction of glutamate-mediated excitotoxicity.
Detailed description
The investigators hypothesis focuses on the effect of riboflavin given for the first three hours of ischemic stroke, as a reducing agent of cerebral glutamate concentration. This administration would produce a reduction of excitotoxic damage and consequently generate clinical improvement, while a lower income and a better functional outcome of patients at three months.
Interventions
DRUGVitamin B2 Streuli®
4ml IV
4ml IV
Sponsors
Castillo, José, M.D.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients older than 18 years, both men and women. 2. Patient or legal representative able to understand and sign the informed consent. 3. Patients with suspected stroke within 3 hours of onset.
Exclusion criteria
1. Women of childbearing age, with potential for pregnancy or breastfeeding. 2. Patients with a score ≥ 2 point 1a in the NIHSS scale. 3. Scale pre-stroke modified Rankin ≥ 2. 4. Inability to prior testing image needed for the study. 5. Previous disorders that may interfere with the interpretation of neurological scales. 6. Treatment with probenecid, tricyclic antidepressants, phenothiazines, streptomycin, erythromycin, tyrothricin, tetracyclines and carbomycin, at the time of inclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of serum glutamate concentration | 7 hours | Difference between serum glutamate concentration from basal (prior to medication infusion) and levels at 3 ± 1 and 6 ± 1 hours, from administered medication, including branch CBG000592 (riboflavin/vitamin B2) and placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of clinical improvement (basal-high) | 3 months | To study the rate of clinical improvement in patients with acute ischemic stroke: clinical improvement according to the formula: (NIHSSbasal-NIHSSalta) / NIHSSbasal x 100 and compared between the two treatment arms. |
| Functional outcome using Rankin Scale at 90 days | 3 months | Study the functional outcome in patients with acute ischemic stroke: modified Rankin scale at 90 days, between two treatment arms. |
| Days of hospitalisation | 3 months | To study the average length of stay in patients with acute ischemic stroke: difference in days, between patient arrival and the patient's discharge, between the two treatment arms. |
| Prognosis of patients using Rankin Scale at 90 days | 3 months | To explore the prognosis of patients without stroke, evaluating modified Rankin scale at 90 days. |
| Number of participants with Adverse Event | 3 months | Safety management: measuring adverse events throughout the study. |
| Serum glutamate concentrations | 7 hours | Variations of serum glutamate curves in patients with acute ischemic stroke between two branches: all concentrations of serum glutamate. |
Countries
Spain
Outcome results
None listed